Association of the use of proton pump inhibitors with adverse cardiovascular and bleeding outcomes after percutaneous coronary intervention in the Japanese real world clinical practice

Cardiovascular Intervention and Therapeutics

Volumn 26, Issue 3, 2011, Pages 222-233

  Kimura, Takeshi ^a   Morimoto, Takeshi ^a   Furukawa, Yutaka ^b   Nakagawa, Yoshihisa ^c   Kadota, Kazushige ^d   Iwabuchi, Masashi ^e   Shizuta, Satoshi ^a   Shiomi, Hiroki ^a   Tada, Tomohisa ^a   Tazaki, Junichi ^a   Kato, Yoshihiro ^a   Hayano, Mamoru ^a   Abe, Mitsuru ^f   Tamura, Takashi ^g   Shirotani, Manabu ^h   Miki, Shinji ⁱ   Matsuda, Mitsuo ^j   Takahashi, Mamoru ^k   Ishii, Katsuhisa ^l   Tanaka, Masaru ^m   Aoyama, Takeshi ⁿ   Doi, Osamu ^o   Hattori, Ryuichi ⁿ   Tatami, Ryozo ^p   Suwa, Satoru ^q   Takizawa, Akinori ^r   Takatsu, Yoshiki ^s   Takahashi, Masaaki ^t   Kato, Hiroshi ^u   Takeda, Teruki ^v   Lee, Jong Dae ^w   Nohara, Ryuji ^x   Tei, Chuwa ^y   Horie, Minoru ^z   Kambara, Hirofumi ^o   Fujiwara, Hisayoshi ^s   Mitsudo, Kazuaki ^d   Nobuyoshi, Masakiyo ^e   Kita, Toru ^b   more..

^a KYOTO UNIVERSITY   (Japan)

^b KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^c TENRI HOSPITAL   (Japan)

^d KURASHIKI CENTRAL HOSPITAL   (Japan)

^e KOKURA MEMORIAL HOSPITAL   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^g JAPANESE RED CROSS WAKAYAMA MEDICAL CENTER   (Japan)

^h KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ MITSUBISHI KYOTO HOSPITAL   (Japan)

^j Kishiwada City Hospital   (Japan)

^k Shimabara Hospital   (Japan)

^l Kansai Denryoku Hospital   (Japan)

^m OSAKA RED CROSS HOSPITAL   (Japan)

ⁿ SHIMADA MUNICIPAL HOSPITAL   (Japan)

^o SHIZUOKA GENERAL HOSPITAL   (Japan)

^p Maizuru Kyosai Hospital   (Japan)

^q JUNTENDO UNIVERSITY SHIZUOKA HOSPITAL   (Japan)

^r SHIZUOKA CITY SHIMIZU HOSPITAL   (Japan)

^s HYOGO PREFECTURAL AMAGASAKI GENERAL MEDICAL CENTER   (Japan)

^t HAMAMATSU ROSAI HOSPITAL   (Japan)

^u NISHI KOBE MEDICAL CENTER   (Japan)

^v Department of Neurosurgery   (Japan)

^w UNIVERSITY OF FUKUI HOSPITAL   (Japan)

^x Kitano Hospital   (Japan)

^y KAGOSHIMA UNIVERSITY   (Japan)

^z SHIGA UNIVERSITY OF MEDICAL SCIENCE HOSPITAL   (Japan)

more..

Author keywords

Angioplasty; Stents; Thrombus

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LANSOPRAZOLE; NICORANDIL; NITRATE; OMEPRAZOLE; RABEPRAZOLE; TICLOPIDINE;

AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DATA BASE; DRUG ELUTING STENT; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITAL DISCHARGE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; STENT THROMBOSIS; TREATMENT DURATION;

EID: 84873648863     PISSN: 18684300     EISSN: 18684297     Source Type: Journal    
DOI: 10.1007/s12928-011-0063-2     Document Type: Article

References (27)

1. Grines CL, Bonow RO, Casey, Jr. DE, Gardner TJ, Lockhart PB, Moliterno DJ, et al., for the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, American Dental Association, and American College of Physicians. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation. 2007; 115: 813-18.
2. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2008; 103: 2890-907.
3. Lai KC, Lam SK, Chu KM, Wong BC, Hui WM, Hu WH, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002; 346: 2033-8.
4. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lakut K, Le Calvez G, et al. Influence of omeprazole on the antiplate- let action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008; 51: 256-60.
5. Sibbing D, Morath T, Stegherr J, Braun S, Vogt W, Hadamitzky M, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost. 2009; 101: 714-9.
6. Small DS, Farid NA, Payne CD, Weerakkody GJ, Li YG, Brandt JT, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol. 2008; 48: 475-84.
7. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009; 301: 937-44.
8. Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009; 180: 713-8.
9. Charlot M, Ahlehoff O, Norgaard ML, Jørgensen CH, Sørensen R, Abildstrøm SZ, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use a nationwide cohort study. Ann Intern Med. 2010; 153: 378-86.
10. Sarafoff N, Sibbing D, Sonntag U, Ellert J, Schulz S, Byrne RA, et al. Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors. Thromb Haemost. 2010; 104: 626-32.
11. Ray WA, Murray KT, Griffin MR, Chung CP, Smalley WE, Hall K, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors a cohort study. Ann Intern Med. 2010; 152: 337-45.
12. O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009; 374: 989-97.
13. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010; 363: 1909-17.
14. Hulot JS, Collet JP, Silvain J, Pena A, Bellemain-Appaix A, Barthélémy O, et al. Cardiovascular Risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration a systematic meta-analysis. J Am Coll Cardiol. 2010; 56: 134-43.
15. Kwok CS, Loke YK. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther. 2010; 31: 810-23.
16. Donahue SR, Flockhart DA, Abernethy DR, Ko JW. Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19. Clin Pharmacol Ther. 1997; 62: 572-7.
17. Tateishi T, Kumai T, Watanabe M, Nakura H, Tanaka M, Kobayashi S. Ticlopidine decreased the in vivo activity of CYP2C19 as measured by omeprazole metabolism. Br J Clin Pharmacol. 1999; 47: 454-7.
18. Ko JW, Desta Z, Soukhova NV, Tracy T, Flockhart DA. In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6. Br J Clin Pharmacol. 2000; 49: 343-51.
19. Ha-Duong NT, Dijols S, Macherey AC, Dansette PM, Mansuy D. Inhibition by ticlopidine and its derivatives of human liver cytochrome P450. Mechanism-based inactivation of CYP2C19 by ticlopidine. Adv Exp Med Biol. 2001; 500: 145-8.
20. Ieiri I, Kimura M, Irie S, Urae A, Otsubo K, Ishizaki T. Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic status. Pharmacogenet Genomics. 2005; 15: 851-9.
21. Hoshino K, Horiuchi H, Tada T, Tazaki J, Nishi N, Kawato M, et al. Clopidogrel resistance in Japanese patients scheduled for percutaneous coronary intervention. Circ J. 2009; 73: 336-42.
22. Jinnai T, Horiuchi H, Makiyama T, Tazaki J, Tada T, Akao M, et al. The impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidgrel in an actual clinical setting in Japan. Circ J. 2009; 73: 1498-503.
23. The GUSTO Investigators. An inter-national randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993; 329: 673-82.
24. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equation for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009; 53: 932-5.
25. Serruys PW, Ong AT, van Herwerden LA, Sousa JE, Jatene A, Bonnier JJ, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol. 2005; 46: 575-81.
26. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007; 356: 1020-9.
27. Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Circulation. 2010; 122: 2619-33.